Mendel Goldfinger

8PUBLICATIONS
46CO-AUTHORS
Respiratory diseasesHaematological tumoursGene and molecular therapyCorrectional theory, offender treatment and rehabilitationPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 06, 2026
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

Lemchukwu Amaeshi, Lauren Laufer, Kateryna Fedorov

|Sep 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri

|Jun 21, 2023
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.

David Levitz, Yogen Saunthararajah, Kateryna Fedorov

|Oct 18, 2022
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.

Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub

|Apr 28, 2022
Efficacy and safety of CAR-T cell therapy in minorities.

Astha Thakkar, Michelly Abreu, Kith Pradhan

|Sep 23, 2021
Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.

Phaedon D Zavras, Aditi Shastri, Mendel Goldfinger

Pageof 2

Frequent Collaborators

4 joint publications

Kira Gritsman

4 joint publications

Nishi Shah

3 joint publications

R Alejandro Sica

3 joint publications

Ioannis Mantzaris